Avid Bioservices Inc (CDMO)

[freethemice]

In anticipation of the releasing of data on the HCC Bavi + sorafenib phase I/II trial at the AACR meeting I have put this info together.
The Child-Pugh score is an estimation of liver function. The Bavi trial only includes patients with Child-Pugh class A. These two
trials used radiological reviews of the responses, as does the Bavi trial. The primary outcome is time to progression (TTP),
secondary outcome is overall survival (OS). I think the difference in survival here is explained by the difference in the
Child-Pugh distribution.

Info on the Child-Pugh score:
http://en.wikipedia.org/wiki/Child-Pugh_score

From the Llovet et al (2008) paper on the phase III HCC trial, shows
how tough it is to treat HCC:
"This finding is important, given the increasing incidence
of the disease around the world and the lack of
efficacious therapeutic options in this setting.
Furthermore, no consistent survival benefits for
anticancer agents in hepatocellular carcinoma have
been recorded in approximately 100 randomized
studies reported during the past 30 years, including
systemic and intraarterial chemotherapy
(predominantly doxorubicin-based or platinumbased),
various hormonal therapies (tamoxifen and
antiandrogens), and immunotherapy (usually interferon alfa)."